Jeremy L. Cobbold

Oxford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Erratum: Noninvasive assessment of liver disease severity in NAFLD and T2D.

Erratum: Noninvasive assessment of liver disease severity in NAFLD and T2D.

Journal: Hepatology (Baltimore, Md.)

Published: July 17, 2026

Human MASLD is a diurnal disease driven by multisystem insulin resistance and reduced insulin availability at night.

Human MASLD is a diurnal disease driven by multisystem insulin resistance and reduced insulin availability at night.

Journal: Cell metabolism

Published: April 03, 2026

Human MASLD is a diurnal disease driven by multisystem insulin resistance and reduced insulin availability at night.

Human MASLD is a diurnal disease driven by multisystem insulin resistance and reduced insulin availability at night.

Journal: Cell metabolism

Published: March 27, 2025

Variations in Estimated Glomerular Filtration Rate Across Countries in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and Their Association With Liver Fibrosis: A Multicenter Study.

Variations in Estimated Glomerular Filtration Rate Across Countries in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and Their Association With Liver Fibrosis: A Multicenter Study.

Journal: MedComm

Published: March 12, 2025

acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study.

acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: November 21, 2023

Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.

Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.

Journal: Hepatology (Baltimore, Md.)

Published: August 25, 2022

PYY plays a key role in the resolution of diabetes following bariatric surgery in humans.

PYY plays a key role in the resolution of diabetes following bariatric surgery in humans.

Journal: EBioMedicine

Published: September 14, 2018

A Rare Cause of Hepatitis.

A Rare Cause of Hepatitis.

Journal: Gastroenterology

Published: July 23, 2018

Rifaximin in non-alcoholic steatohepatitis: An open-label pilot study.

Rifaximin in non-alcoholic steatohepatitis: An open-label pilot study.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: March 07, 2017

Changes in Liver Volume in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy.

Changes in Liver Volume in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy.

Journal: Journal of clinical and experimental hepatology

Published: October 10, 2015

Piloting a multidisciplinary clinic for the management of non-alcoholic fatty liver disease: initial 5-year experience.

Piloting a multidisciplinary clinic for the management of non-alcoholic fatty liver disease: initial 5-year experience.

Journal: Frontline gastroenterology

Published: February 21, 2013

Lipid profiling of pre-treatment liver biopsy tissue predicts sustained virological response in patients with chronic hepatitis C.

Lipid profiling of pre-treatment liver biopsy tissue predicts sustained virological response in patients with chronic hepatitis C.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: June 13, 2012

Showing 1-12 of 17

Last Updated: 09/26/2026